ZA932757B - Agents for treating substance abuse disorders - Google Patents

Agents for treating substance abuse disorders

Info

Publication number
ZA932757B
ZA932757B ZA932757A ZA932757A ZA932757B ZA 932757 B ZA932757 B ZA 932757B ZA 932757 A ZA932757 A ZA 932757A ZA 932757 A ZA932757 A ZA 932757A ZA 932757 B ZA932757 B ZA 932757B
Authority
ZA
South Africa
Prior art keywords
pct
abuse
agents
substance abuse
abuse disorders
Prior art date
Application number
ZA932757A
Other languages
English (en)
Inventor
Anders Bjork
Gunnar Andersson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of ZA932757B publication Critical patent/ZA932757B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pyridine Compounds (AREA)
ZA932757A 1992-04-21 1993-04-20 Agents for treating substance abuse disorders ZA932757B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders

Publications (1)

Publication Number Publication Date
ZA932757B true ZA932757B (en) 1993-10-28

Family

ID=20386004

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932757A ZA932757B (en) 1992-04-21 1993-04-20 Agents for treating substance abuse disorders

Country Status (26)

Country Link
US (1) US5565455A (ko)
EP (1) EP0637242B1 (ko)
JP (1) JP3245642B2 (ko)
KR (1) KR100321319B1 (ko)
AT (1) ATE184484T1 (ko)
AU (1) AU659941B2 (ko)
BG (1) BG62154B1 (ko)
BR (1) BR9306361A (ko)
CA (1) CA2118512C (ko)
CZ (1) CZ281296B6 (ko)
DE (1) DE69326459T2 (ko)
DK (1) DK0637242T3 (ko)
EE (1) EE02974B1 (ko)
ES (1) ES2139007T3 (ko)
GR (1) GR3032030T3 (ko)
HU (1) HU223463B1 (ko)
IL (1) IL105449A (ko)
NO (2) NO308827B1 (ko)
PH (1) PH31051A (ko)
RO (1) RO117150B1 (ko)
RU (1) RU2126254C1 (ko)
SE (1) SE9201239D0 (ko)
SK (1) SK279940B6 (ko)
UA (1) UA27884C2 (ko)
WO (1) WO1993020821A1 (ko)
ZA (1) ZA932757B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
SE9601708D0 (sv) * 1996-05-06 1996-05-06 Pharmacia Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
DK1027336T3 (da) 1997-10-27 2005-01-24 Neurosearch As Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
EP1551372B8 (en) 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2958694A (en) * 1959-06-22 1960-11-01 Janssen Paul Adriaan Jan 1-(aroylalkyl)-4-(2'-pyridyl) piperazines
US2979508A (en) * 1959-10-12 1961-04-11 Paul A J Janssen Heterocyclic derivatives of 1-phenyl-omega-(piperazine) alkanols
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
NO308827B1 (no) 2000-11-06
IL105449A (en) 1998-02-22
UA27884C2 (uk) 2000-10-16
WO1993020821A1 (en) 1993-10-28
SK279940B6 (sk) 1999-06-11
EP0637242A1 (en) 1995-02-08
EP0637242B1 (en) 1999-09-15
RU2126254C1 (ru) 1999-02-20
CA2118512A1 (en) 1993-10-28
AU659941B2 (en) 1995-06-01
JPH08503449A (ja) 1996-04-16
DK0637242T3 (da) 2000-03-27
NO20004169D0 (no) 2000-08-21
NO943977L (no) 1994-10-20
BG62154B1 (bg) 1999-04-30
RU94045866A (ru) 1996-10-20
HUT71420A (en) 1995-11-28
CA2118512C (en) 2004-07-27
DE69326459T2 (de) 2000-03-23
IL105449A0 (en) 1993-08-18
BR9306361A (pt) 1998-06-30
NO943977D0 (no) 1994-10-20
ATE184484T1 (de) 1999-10-15
NO20004169L (no) 1994-10-20
SK126994A3 (en) 1995-07-11
ES2139007T3 (es) 2000-02-01
RO117150B1 (ro) 2001-11-30
GR3032030T3 (en) 2000-03-31
KR950701221A (ko) 1995-03-23
DE69326459D1 (de) 1999-10-21
PH31051A (en) 1998-02-03
HU9403020D0 (en) 1994-12-28
AU4043793A (en) 1993-11-18
CZ281296B6 (cs) 1996-08-14
NO318461B1 (no) 2005-03-21
JP3245642B2 (ja) 2002-01-15
KR100321319B1 (ko) 2002-07-27
BG99129A (bg) 1995-08-28
HU223463B1 (hu) 2004-07-28
EE02974B1 (et) 1997-04-15
US5565455A (en) 1996-10-15
SE9201239D0 (sv) 1992-04-21
CZ260694A3 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
GR3032030T3 (en) Agents for treating substance abuse disorders.
HUT64696A (en) Method for production of preparations containing diphenyl-butyl-piperazine-carboxamides for the treatment of drug addict and drug abuse
MY109862A (en) A short infusion methods for administration of paclitaxel
CA2164291A1 (en) Methods and pharmaceutical compositions useful for treating neurological disorders
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
Coccaro Psychopharmacological studies in patients with personality disorders: Review and perspective.
Levine et al. The effect of centrally administered naloxone on deprivation and drug-induced feeding
DE3778008D1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
KR890011572A (ko) 정신 기능을 증진시키는 방법
Baughman The safety record of buspirone in generalized anxiety disorder.
DE69307705D1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
KR940003550A (ko) 노인성 치매 예방 및 치료방법
KR910005868A (ko) 신규 치료법